{
    "clinical_study": {
        "@rank": "146122", 
        "arm_group": {
            "arm_group_label": "Doxycycline", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The tetracycline antibiotic doxycycline disrupts A beta amyloid  fibrils (AB) in Alzheimer's\n      disease,  transthyretin (ATTR) amyloid fibrils in familial amyloidotic polyneuropathy, and\n      immunoglobulin light chain (AL) amyloid fibrils in transgenic mouse models of disease. If\n      untreated, amyloid deposits impair organ function, affecting the morbidity and mortality of\n      patients.\n\n      This single-center, twelve-month, open-label, prospective, pilot phase II study aims to\n      determine whether doxycycline reduces amyloid deposits and improves organ function in\n      patients with systemic or localized amyloidosis.\n\n      The investigators plan to enroll patients with measurable amyloid disease according to\n      internationally-accepted diagnostic criteria. Patients must have stable organ function at\n      enrollment. Eligible subjects not receiving active treatments for amyloidosis affecting\n      their kidneys, heart, aerodigestive tracts, peripheral or autonomic nervous system(s),\n      lungs, eyes, skin, bladder, or breasts will undergo evaluations at baseline, 6 months, and\n      12 months - or more frequently as clinically indicated.\n\n      Over 45 years experience indicates doxycycline is a safe, well tolerated antibiotic. The\n      investigators will use standard grading systems to assess doxycycline response following\n      twelve months of treatment."
        }, 
        "brief_title": "Safety and Effect of Doxycycline in Patients With Amyloidosis", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Amyloidosis", 
        "condition_browse": {
            "mesh_term": "Amyloidosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 or older\n\n          -  Biopsy-proven amyloidosis\n\n          -  Biochemical or clinical evidence of amyloid induced end-organ dysfunction\n\n        Exclusion Criteria:\n\n          -  Concurrent use of other tetracyclines\n\n          -  Ongoing active treatment for amyloidosis\n\n          -  Pregnancy or unwillingness to use contraception by women of childbearing age\n\n          -  Doxycycline drug allergy/hypersensitivity\n\n          -  ECOG performance status > 3\n\n          -  NYHA class > 3\n\n          -  Renal insufficiency (estimated creatinine clearance < 25 ml/min)\n\n          -  Transaminitis (AST or ALT > 5 times upper limit of normal)\n\n          -  Diabetes mellitus or hemoglobin A1C > 6.2%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677286", 
            "org_study_id": "H-31546"
        }, 
        "intervention": {
            "arm_group_label": "Doxycycline", 
            "description": "100mg by mouth twice daily for 1 year.", 
            "intervention_name": "Doxycycline", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Doxycycline", 
                "Doxycycline hyclate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "AL Amyloidosis", 
            "Primary Amyloidosis", 
            "Hereditary Amyloidosis", 
            "Familial Amyloidosis", 
            "SSA Amyloidosis", 
            "Senile Systemic Amyloidosis", 
            "AA Amyloidosis", 
            "Secondary Amyloidosis", 
            "Localized Amyloidosis", 
            "Systemic Amyloidosis"
        ], 
        "lastchanged_date": "May 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02118"
                }, 
                "name": "Boston University"
            }, 
            "investigator": {
                "last_name": "John L Berk, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Doxycycline in Patients With Amyloidosis", 
        "overall_contact": {
            "email": "Samantha.Pappin@bmc.org", 
            "last_name": "Samantha Pappin", 
            "phone": "617-638-4494"
        }, 
        "overall_official": {
            "affiliation": "Boston University", 
            "last_name": "John L Berk, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Amyloid nephropathy: 24 hour urine protein excretion, creatinine clearance\nAmyloid cardiomyopathy: cardiac biomarkers (BNP, Troponin I), echo parameters (IVSd, longitudinal strain, diastolic indices [e/e']), ECG\nAmyloid peripheral neuropathy: Neurologic Impairment Score-Lower Limb (NIS-LL), modified body mass index (mBMI)\nAmyloid autonomic neuropathy: postural blood pressures, heart rate variability, mBMI\nLocalized amyloidosis:\nairway -- PFTs, CT imaging, endoscopic visualization\ngastrointestinal -- endoscopic visualization\nbladder -- CT imaging, cystoscopy, urodynamics\nskin -- direct measures of disease", 
            "measure": "Composite measures specific to the organ system affected by amyloidosis at study entry", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "reference": [
            {
                "PMID": "12724338", 
                "citation": "Cardoso I, Merlini G, Saraiva MJ. 4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003 May;17(8):803-9."
            }, 
            {
                "PMID": "16449795", 
                "citation": "Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006 Feb;20(2):234-9."
            }, 
            {
                "PMID": "11163366", 
                "citation": "Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001 Jan 5;487(3):404-7."
            }, 
            {
                "citation": "Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. Journal of Translational Medicine. 2010;8:74."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677286"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Boston University", 
            "investigator_full_name": "John L. Berk", 
            "investigator_title": "Clinical Director, Amyloid Treatment & Research Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Quality of Life (SF-36)", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Motor, sensory, autonomic measures of neuropathy", 
                "measure": "Kumamoto neurologic score", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Boston University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boston University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}